Τόμος 28 (2010) – Τεύχος 2 – Άρθρο 13 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 28 (2010) – Issue 2 – Article 13 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ιωάννης Κανονίδης

Αναπληρωτής Καθηγητής Καρδιολογίας, Β΄ Καρδιολογική Κλινική, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Ioannis Kanonidis

Associate Professor of Cardiology, 2^nd Department of Cardiology, Medical School, Aristotle University, Thessaloniki-Greece

2. Packer M., Carver J.R., Rodeheffer R.J., et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325: 1468-1475 (1991)

3. Cohn J.N., Johnson G., Ziesche S., et al.: A comparison of enalapril with hydralazine – isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325: 303-310 (1991)

4. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive hear failure. Results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316: 1429-1435 (1987)

5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325: 293-302 (1991)

6. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327: 685-691(1992)

7. Granger C.B., McMurray J.J., Yusuf S., et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776 (2003)

8. Pfeffer M.A., Swedberg K., Granger C.B., et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759-766 (2003)

9. Pitt B., Zannad F., Remme W.J. et al.: The effect of spiro-nolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341: 709-717 (1999)

10. Pitt B., Remme W., Zannad F., et al.: Elperenone, a selec-tive aldosterone blocker, in patients with left ventricular dys-function after myocardial infarction. N. Engl. J. Med. 348: 1309-1321 (2003)

11. Cohn J.N.: Beta-blockers in heart failure. Eur. Heart J. 19(Suppl. F): F52-F55 (1998)

12. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al.: Com-parison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET`): randomized controlled trial. Lancet 362: 7-13 (2003)

13. Clenland J.G.F., Poole-Wilson P.A.: ACE inhibitors for heart failure: A question of dose. Br. Heart J. 72: S106-10 (1994)

14. Clenland J.G.F., Poole-Wilson P.A.: The Clinical course of heart failure and its modification by the ACE inhibitors: Insights from recent clinical trials. Eur. Heart J. 72: S125-130 (1994)

15. Australia/New Zealand Heart Failure Research Collaborative Group: Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349: 375-80 (1997)

16. Waagstein F., Caidahl K., Wallentin I., Bergh C., Hjalmarson A.: Long-term b-blockade in dilated cardiomyopathy. Cir-culation 80: 551-563 (1989)

17. Waagstein F., Bristow M.R., Swedberg K., et al.: For the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441-1446 (1993)

18. Olsen S.L., Gilbert E.M., Renlund D.G., et al.: Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind study. J. Am. Coll. Cardiol. 25: 1225-1231 (1995)

19. Woodley S.L., Gilbert E.M., Anderson J.L., et al.: b-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 2426-2441 (1991)

20. CIBIS Investigators and Comittees: A randomized trial of b-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90: 1765-1773 (1994)

21. Ambrosioni E., Borghi C., Magnani B.: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N. Engl. J. Med. 332: 80-85 (1995)

22. The AIRE Study Group: Effect of ramipril on mortality and morbidity of survivors of the acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821-828 (1993)

23. Kelly R.A., Smith T.W.: Digoxin in heart failure: Implications of recent trial. J. Am. Coll. Cardiol. 22(Suppl A): 107A-112A (1993)

24. Arnold S.B., Byrd R.C., Meister W., et al.: Long-term digitalis therapy improves left ventricular function in heart failure. N. Engl. J. Med. 303: 1443-1448 (1980)

25. Just H., Drexler H., Taylor S.H., et al.: Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo controlled multicentre study. The CADS Study Group. Herz 18(Suppl 1): 436-443 (1993)

26. Gilbert E.M., Abraham W.T., Olsen S., et al.: Comparative hemodynamic left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817-25 (1996)

27. Packer M., Bristow M.R., Cohn J.N., et al.: Effect of carvedilol on morbidity and mortality in chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334: 1349-1355 (1996)